Get started
Author

Rüdiger Liersch

Observed name: R. Liersch
Observed institution: Clemenshospital Münster
ORCID: 0000-0003-0610-345X
Observed ORCID: 0000-0003-0610-345X
OpenAlex ID: A5068486169
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · D. Miles, J. Gligorov, et al. · Annals of Oncology · 786
PDF
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
2023 · Caicun Zhou, Minu K Srivastava, et al. · Journal for ImmunoTherapy of Cancer · 22
PDF
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
2024 · Petra Langerbeins, Sandra Robrecht, et al. · Journal of Clinical Oncology · 21
Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
2022 · Nadine Kutsch, Christian Pallasch, et al. · HemaSphere · 15
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial
2025 · Florian Simon, Rudy Ligtvoet, et al. · Blood · 14
PDF
80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
2022 · E. Felip, N.K. Altorki, et al. · Annals of Oncology · 14
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)—an AIO/ABCSG trial
2026 · G. Folprecht, S. Stasik, et al. · Annals of Oncology · 9
MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
2023 · E. Felip, M. Srivastava, et al. · Journal of Thoracic Oncology · 7
PDF
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
2025 · Christian Schmidt, Gabriel Scheubeck, et al. · Haematologica · 3
PDF
1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
2023 · N.K. Altorki, M. Reck, et al. · Annals of Oncology · 2
PDF
Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry
2026 · Alexander Grunenberg, Birgit Schmelzle, et al. · Leukemia
PDF
Erratum to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”
2025 · Christian Schmidt, Gabriel Scheubeck, et al. · Haematologica
PDF
P630: Safety and Treatment Adherence With Acalabrutinib in Very Old (≥80y) And/or Frail Patients With Chronic Lymphocytic Leukemia (cll) - Interim Safety Analysis of the Ongoing Phase-ii Cll-frail Trial
2023 · Florian Simon, Rudy Ligtvoet, et al. · HemaSphere
Works count: 13
Citation count: 893
H-index: 7
I10-index: 6
Year
Topic
Type